AITRICS, a medical artificial intelligence (AI) company, announced on the 1st that it has attracted a total of 35 billion won in Series C investment from 9 domestic and foreign venture capital firms and financial institutions.
This round included existing investors, including Premier Partners, Hanriver Partners, Mirae Asset Venture Investment, and Shinyoung Securities-BSK Investment. New investors included KB Securities-Solidus Investment, SV Investment, and Mirae Asset Capital.
AITRIX stated that this investment recognizes its technological prowess, clinical effectiveness, and global expansion potential. The secured funds will be focused on core strategies, including enhancing the functionality of AITRICS-VC (Vital Care), a solution for predicting deterioration in hospitalized patients, and V.Doc Pro, a co-pilot AI solution for medical professionals, as well as research and development of new pipelines.
Overseas operations are also accelerating. The company established a Japanese subsidiary in March to establish an operational base and is pursuing expansion into Asia, starting with Japan and expanding to Vietnam and Hong Kong. Furthermore, it established a US subsidiary in 2023, laying the foundation for expansion into North America. Recently, it has partnered with the Mayo Clinic platform to validate its model and flesh out its global strategy.
Kim Gwang-jun, CEO of AITRIX, said, “Thanks to the investors who have shown continued trust, we have been able to reaffirm the company’s growth potential and direction,” and “The secured funds will play a significant role in promoting our mid- to long-term strategy and strengthening our competitiveness.”
An SV Investment official said, “We highly value AITRIX’s innovative AI solutions, clinical performance, and clear strategy,” and added, “This investment will further accelerate the expansion of indications and entry into the global market.”
- See more related articles
You must be logged in to post a comment.